Globally, in the year 2016, 9.6 million people died of cancer and 90% of those deaths were due to metastasis, i.e. spreading of the primary tumor to other parts of the body (1). Five-year survival rates are 80% for most types of primary carcinomas but drops to ~30% once the tumor metastasizes (2). As of 2019, all but one of the 215+ approved cancer drugs do not address metastasis, for which there are almost no treatments.
Introducing Mestastop, who aims to make a difference by understanding metastasis biology and addressing it, for both diagnostics and discovery.
1. AACR Cancer Progress Report, 2018
2. Nature Reviews Cancer, 2016, 16, 2001
Our vision is to be “the metastasis specialists”, by creating a world class R&D focused on metastasis, leveraging the unique strengths of being in India. We are bringing together a cross functional team, trained in discovery, diagnostics and AI. They would be supported by the state-of-the-art infrastructure available in India’s best bioscience incubators, working to the highest standards of data integrity.
Nexus Venture Partners
“Arnab’s passion to solve this problem is admirable”
Dr. D.C Doval
“If Mestastop can predict metastasis probability of primary cancer patients, that will be a game changer for doctors”
Dr. A. K Vaid
“Mestastop provides a great opportunity at finding solutions to the unmet medical needs in cancer care”
Dr. A. Kamath
“Concept-wise, it is a much-needed approach to address metastasis; looks very interesting and perhaps doable with Arnab’s keen interest and passion”
“It would be our pleasure to support a passionate entrepreneur and a bold vision”